Letter to the editor

Current biological and pharmacological updates on wogonin

Sarita Rawat¹, Gaurav Gupta¹[*], Sachchidanand Pathak¹, Santosh Kumar Singh¹, Himmat Singh¹, Anurag Mishra¹, Ritu Gilhotra¹, Alaa A. A. Aljabali², Harish Dureja³, Murtaza M. Tambuwala⁴, Dinesh K. Chellappan⁵, Kamal Dua^6,7,8

¹School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India

²Faculty of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan

³Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana 124001, India

⁴School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, County, Londonderry, BT52 1SA, Northern Ireland, United Kingdom

⁵Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia 57000

⁶Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), Ultimo, NSW 2007, Australia

⁷Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia

⁸Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, The University of Newcastle (UoN), Callaghan, NSW 2308, Australia

EXCLI J 2020;19:Doc635



Dear Editor,

Wogonin (5, 7-Dihydroxy-8-methoxy flavone) is a traditional naturally occurring flavonoid derived from the root extract of Chinese medicine, named Scutellaria baicalensis Georgi. Wogonin contains various biological properties which include allergic diseases, anti-cancer therapy, and anti-inflammatory activities. Wogonin also shows the effects of removing toxins and cleansing the heart (Ancuceanu et al., 2019[1]). The anticancer therapeutic activity of wogonin has been shown by the regulation of different cell signaling pathways, which includes protein kinase B pathway (serine-threonine kinase) and AMP-activated protein kinase pathways (Bei et al., 2020[2]). Wogonin also shows positive therapeutic anticancer effects in breast cancer by inhibiting the 5-LO/BLT2/ERK/IL-8/MMP-9 signaling cascade and establishes a major pharmacological anticancer activity (Bibi et al., 2019[3]). Current biological and pharmacological updates on wogonin have been reviewed (Table 1(Tab. 1); References in Table 1: Du et al., 2019[4]; Ewendt and Foller, 2019[5]; Fang et al., 2019[6]; Gao et al., 2019[7]; Gharari et al., 2020[8]; Hanioka et al., 2020[9]; Hong et al., 2020[10]; Huang et al., 2020[11]; Jiang et al., 2019[12]; Jiao et al., 2019[13]; Khan and Kamal, 2019[14][15]; Khushdil et al., 2019[16]; Kim et al., 2019[17]; Kong et al., 2019[18]; Liang et al., 2019[19]; Liau et al., 2019[20]; Luo et al., 2019[21]; Oomen et al., 2020[22]; Tan et al., 2019[23]; Wang and Cui, 2019[24]; Wang et al., 2019[25][26]; Wang et al., 2020[27]; Xing et al., 2019[28][29]; Zhang et al., 2019[30]).

Conflict of interest

The authors declare no conflict of interest.

References